株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

医薬品卸売・流通の世界市場の予測:2020年~2030年

Pharma Wholesale and Distribution Market Forecasts 2020-2030: Branded Drugs, Generic Drugs, US, China, Japan, Germany, France, Brazil, Italy, Spain, UK, India, Russia, RoW

発行 Visiongain Ltd 商品コード 247784
出版日 ページ情報 英文 217 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1GBP=147.30円で換算しております。

ご注意:
Single UserとDepartmentalライセンスは、DRM (デジタル著作権管理システム) 付PDFになります。制限内容は、上記ライセンスの[詳細]アイコンをクリックしてご確認ください。

Back to Top
医薬品卸売・流通の世界市場の予測:2020年~2030年 Pharma Wholesale and Distribution Market Forecasts 2020-2030: Branded Drugs, Generic Drugs, US, China, Japan, Germany, France, Brazil, Italy, Spain, UK, India, Russia, RoW
出版日: 2019年09月30日 ページ情報: 英文 217 Pages
概要

医薬品卸売・流通市場は、2020年~2025年のCAGR (複合年間成長率) で、5%の成長が予測されています。

当レポートでは、世界の医薬品卸売・流通市場について調査分析し、市場概要、世界市場の予測、主要国市場の予測、主要企業などについて、体系的な情報を提供しています。

第1章 レポート概要

第2章 医薬品卸売・流通のイントロダクション

  • 医薬品卸売業の役割
  • 流通チェーン
  • 収益と利益の生成

第3章 世界の医薬品卸売・流通市場

  • 世界の医薬品卸売・流通市場
  • 医薬品卸売・流通産業:世界市場の予測
  • ブランド/ジェネリック医薬品:収益 vs. 利益

第4章 医薬品卸売・流通産業:主要国市場

  • 主要国市場:米国が優勢
  • 主要国市場の将来:引き続き米国が優勢か?
  • 米国
  • EU5ヶ国
  • 日本
  • 中国
  • ブラジル
  • インド
  • ロシア
  • 結論

第5章 主要な医薬品卸売・流通業者

  • 主要企業
  • 主要企業:促進要因・抑制要因
  • McKesson Corporation
  • Cardinal Health
  • AmerisourceBergen
  • Walgreens Boots Alliance
  • Medipal Holdings Corporation
  • Phoenix Group
  • Sinopharm Group Co. Ltd.
  • Alfresa Holdings Corporation
  • スズケン
  • Shanghai Fosun Pharmaceuticals Co. Ltd.
  • CR Pharmaceuticals
  • Morris and Dickson
  • CuraScript SD
  • Mutual Drug Company

第6章 医薬品卸売・流通市場の定性分析

  • 強みと弱み
  • 機会と脅威
  • STEP分析

第7章 結論

付録

図表

List of Tables

  • TABLE 2.1 USE OF DTP MODEL IN THE UK, 2007-2012
  • TABLE 3.1 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN), AGR (%), CAGR (%), 2018-2030
  • TABLE 3.2 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: BRANDED DRUGS, GENERIC DRUGS AND OTHERS, REVENUE ($BN) FORECASTS, AGR (%), CAGR (%) AND MARKET SHARES (%), 2018-2030
  • TABLE 3.3 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS: REVENUE ($BN) AND MARKET SHARE (%) FORECAST, 2018-2030
  • TABLE 3.4 WHOLESALE AND DISTRIBUTION OF GENERIC DRUGS: REVENUE ($BN) AND MARKET SHARE (%) FORECAST, 2018-2030
  • TABLE 4.1 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: REVENUES ($BN) AND MARKET SHARE (%), 2018
  • Table 4.2 Pharma Wholesale & Distribution Leading National Markets: Revenue ($bn) Forecasts, AGR (%) and CAGR (%), 2018-2030
  • TABLE 4.3 US PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.4 US PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.5 PRICE CONTROLS IN EUROPE, 2016
  • TABLE 4.6 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECASTS, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.7 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.8 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.9 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.10 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.11 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.12 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.13 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.14 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.15 UK PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.16 UK PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.17 PERCENTAGE OF THE POPULATION AGES 60+ IN THE US, EUROPE, JAPAN, CHINA AND INDIA, 2015 AND 2030
  • TABLE 4.18 JAPANESE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: DRUG PRICE REVISION GROWTH (%), 2006-2016
  • TABLE 4.19 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.20 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.21 CHINESE PHARMA WHOLESALE & DISTRIBUTION: REVENUE ($BN) AND MARKET SHARES (%) OF LEADING COMPANIES, 2018
  • TABLE 4.22 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.23 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.24 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.25 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.26 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.27 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.28 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, AGR (%) AND CAGR (%), 2018-2030
  • TABLE 4.29 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • TABLE 5.1 LEADING COMPANIES IN THE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: REVENUES ($BN) AND MARKET SHARES (%), 2018
  • TABLE 5.2 MCKESSON: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2015-2019
  • TABLE 5.3 ACQUISITIONS BY MCKESSON, 2007-2019
  • TABLE 5.4 CARDINAL HEALTH: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
  • TABLE 5.5 SELECTED ACQUISITIONS BY CARDINAL HEALTH AND THEIR LINE OF BUSINESS, 2007-2019
  • TABLE 5.6 AMERISOURCEBERGEN: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
  • TABLE 5.7 ACQUISITIONS BY AMERISOURCEBERGEN AND THEIR LINE OF BUSINESS, 2007-2019
  • TABLE 5.8 WALGREENS BOOTS ALLIANCE: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
  • TABLE 5.9 MEDIPAL: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
  • TABLE 5.10 PHOENIX GROUP: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
  • TABLE 5.11 SINOPHARM: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
  • TABLE 5.12 ALFRESA: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
  • TABLE 5.13 SUZUKEN: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
  • TABLE 5.14 SHANGHAI FOSUN PHARMA: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
  • TABLE 5.15 CR PHARMACEUTICALS: HISTORICAL REVENUES ($BN), AGR (%) AND CAGR (%), 2014-2018
  • TABLE 6.1 THE PHARMACEUTICAL W&D MARKET: STRENGTHS AND WEAKNESSES
  • TABLE 6.2 THE PHARMACEUTICAL W&D MARKET: OPPORTUNITIES AND THREATS, 2019-2030
  • TABLE 6.3 STRENGTHS AND WEAKNESSES OF THE DTP DISTRIBUTION MODEL
  • TABLE 6.4 ITR RATINGS AND CORRESPONDING REIMBURSEMENT RATES
  • TABLE 6.5 SOCIAL, TECHNOLOGICAL, ECONOMIC AND POLITICAL FACTORS INFLUENCING THE PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET (STEP ANALYSIS)

List of Figures

  • FIGURE 2.1 ROUTES OF DRUG DISTRIBUTION
  • FIGURE 3.1 THE GLOBAL PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 3.2 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN), 2018-2030
  • FIGURE 3.3 BRANDED DRUGS, GENERIC DRUGS, AND OTHERS: MARKET SHARES (%), 2018
  • FIGURE 3.4 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: WORLD MARKET FORECAST ($BN) BY CATEGORY, 2018-2030
  • FIGURE 3.5 BRANDED DRUGS, GENERIC DRUGS AND OTHERS: MARKET SHARES (%), 2025
  • FIGURE 3.6 BRANDED DRUGS, GENERIC DRUGS AND OTHERS: MARKET SHARES (%), 2030
  • FIGURE 3.7 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS, GENERIC DRUGS AND OTHERS: REVENUE FORECASTS ($BN), 2018-2030
  • FIGURE 3.8 WHOLESALE AND DISTRIBUTION OF BRANDED DRUGS: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 3.9 WHOLESALE AND DISTRIBUTION OF GENERIC DRUGS: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.1 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: SHARES (%), 2018
  • FIGURE 4.2 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: SHARES (%), 2025
  • FIGURE 4.3 PHARMA WHOLESALE & DISTRIBUTION LEADING NATIONAL MARKETS: SHARES (%), 2030
  • FIGURE 4.4 US PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKET: SHARE (%), 2018
  • FIGURE 4.5 US PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.6 US PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.7 US PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 4.8 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET SHARES (%), 2018
  • FIGURE 4.9 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET SHARES (%), 2025
  • FIGURE 4.10 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET SHARES (%), 2030
  • FIGURE 4.11 EU5 PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECASTS, 2018-2030
  • FIGURE 4.12 EU PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 4.13 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.14 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.15 GERMAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 4.16 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.17 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.18 FRENCH PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 4.19 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.20 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.21 ITALIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS, 2017
  • FIGURE 4.22 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.23 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.24 SPANISH PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS, 2017
  • FIGURE 4.25 UK PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN), 2018-2030
  • FIGURE 4.26 UK PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.27 UK PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 4.28 PERCENTAGE OF THE POPULATION AGES 65+ IN THE US, EUROPE, JAPAN, CHINA AND INDIA, 2015 AND 2030
  • FIGURE 4.29 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.30 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.31 JAPANESE PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 4.32 CHINESE PHARMA WHOLESALE & DISTRIBUTION: MARKET SHARES (%), 2018
  • FIGURE 4.33 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.34 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.35 CHINESE PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 4.36 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.37 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.38 BRAZILIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 4.39 PHARMA WHOLESALE & DISTRIBUTION MODEL IN INDIA
  • FIGURE 4.40 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.41 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.42 INDIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 4.43 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.44 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET BY DRUGS CATEGORY: REVENUE ($BN) FORECAST, 2018-2030
  • FIGURE 4.45 RUSSIAN PHARMA WHOLESALE & DISTRIBUTION MARKET: DRIVERS AND RESTRAINTS
  • FIGURE 5.1 LEADING PHARMACEUTICAL WHOLESALE AND DISTRIBUTION COMPANIES: MARKET SHARES (%), 2018
  • FIGURE 5.2 LEADING PHARMACEUTICAL W&D COMPANIES: DRIVERS AND RESTRAINTS
  • FIGURE 5.3 MCKESSON: HISTORICAL REVENUE ($BN), 2015-2019
  • FIGURE 5.4 MCKESSON: DRIVERS AND RESTRAINTS
  • FIGURE 5.6 CARDINAL HEALTH: HISTORICAL REVENUE ($BN), 2014-2018
  • FIGURE 5.7 CARDINAL HEALTH: DRIVERS AND RESTRAINTS
  • FIGURE 5.8 AMERISOURCEBERGEN: HISTORICAL REVENUE ($BN), 2014-2018
  • FIGURE 5.9 AMERISOURCEBERGEN: DRIVERS AND RESTRAINTS
  • FIGURE 5.10 WALGREENS BOOTS ALLIANCE: HISTORICAL REVENUE ($BN), 2014-2018
  • FIGURE 5.11 WALGREEN BOOTS ALLIANCE: DRIVERS AND RESTRAINTS
  • FIGURE 5.12 MEDIPAL: HISTORICAL REVENUE ($BN), 2014-2018
  • FIGURE 5.13 MEDIPAL HOLDINGS: DRIVERS AND RESTRAINTS
  • FIGURE 5.14 PHOENIX GROUP: HISTORICAL REVENUE ($BN), 2014-2018
  • FIGURE 5.15 PHOENIX GROUP DRIVERS AND RESTRAINTS
  • FIGURE 5.16 SINOPHARM: HISTORICAL REVENUE ($BN), 2014-2018
  • FIGURE 5.17 SINOPHARM GROUP: DRIVERS AND RESTRAINTS
  • FIGURE 5.18 ALFRESA: HISTORICAL REVENUE ($BN), 2014-2018
  • FIGURE 5.19 ALFRESA: DRIVERS AND RESTRAINTS
  • FIGURE 5.20 SUZUKEN: HISTORICAL REVENUE ($BN), 2014-2018
  • FIGURE 5.21 SUZUKEN: DRIVERS AND RESTRAINTS
  • FIGURE 5.22 SHANGHAI FOSUN PHARMA: HISTORICAL REVENUE ($BN), 2014-2018
  • FIGURE 5.23 SHANGHAI FOSUN PHARMACEUTICALS: DRIVERS AND RESTRAINTS
  • FIGURE 5.24 CR PHARMACEUTICALS: HISTORICAL REVENUE ($BN), 2014-2018
  • FIGURE 6.1 COMPARISON OF THE WHOLESALE AND DTP ROUTES OF DISTRIBUTION
  • FIGURE 7.1 PHARMACEUTICAL WHOLESALE AND DISTRIBUTION: GLOBAL MARKET FORECASTS ($BN) BY SUBMARKET, 2018-2030
  • FIGURE 7.2 LEADING NATIONAL PHARMACEUTICAL WHOLESALE AND DISTRIBUTION MARKETS: REVENUE PROJECTIONS ($BN), 2018, 2025 AND 2030

List of Companies and Organizations Mentioned in the Report:

  • 36.6
  • AAH Pharmaceuticals
  • AccessClosure
  • Acofarma (Asociación Cooperativas Farmacéuticas)
  • ADG Apotheken-Dienstleistungsgesellschaft mbH
  • Admenta
  • Alfresa Fine Chemical Corporation
  • Alfresa Holdings
  • Alliance Boots
  • Alliance Healthcare
  • Alliance Santé
  • Alliance UniChem
  • AmeriSource Health
  • AmerisourceBergen
  • AmerisourceBergen Canada
  • AmerisourceBergen Drug Corporation (ABDC)
  • AmerisourceBergen specialty Group (ABSG)
  • Apollo Medical Holdings
  • ASTEC Co., Ltd.
  • ASTIS Co., Ltd.
  • Athos Farma
  • ATOL CO., LTD.
  • Azwell
  • Bayer
  • BENU Apotheek
  • Bergen Brunswig
  • Biologics Inc
  • Boots Group
  • Bristol-Myers Squibb
  • Brocacef Groep NV
  • Brocacef Holding
  • Bundesverband des Pharmazeutischen Grosshandel
  • Cardinal Health
  • Caremark Rx
  • Celesio AG
  • CERP Bretagne Nord
  • CERP Rhin Rhone Mediterranee
  • CERP Rouen
  • Chiyaku Co
  • Chuounyu Co., Ltd.
  • Cloumed Corporation
  • Cofares
  • Comifar
  • Cordis
  • CoverMyMeds
  • CoverMyMeds LLC
  • CVS Caremark
  • CVS Corporation
  • CVS Health Corporation
  • Cystic Fibrosis Foundation Pharmacy, LLC
  • Daiichi Sankyo Propharma Co.
  • Dong Ying (Jiangsu) Pharmaceuticals Co., Ltd.
  • Drogarias Tamoio
  • Drug Trading Company Ltd
  • Dutch ACM
  • Emart Company
  • ENSHU YAKUHIN CO., LTD.
  • Ethicon
  • EVERLTH AGROTECH Co., Ltd.
  • EVERLTH Co., Ltd.
  • Farcopa Distribuzione
  • Fukujin Co.
  • Good Service Co
  • Guangzhou Pharmaceutical Company Ltd.
  • Guangzhou Pharmaceuticals Corporation
  • Harvard Drug
  • Hedef Alliance
  • Hefame
  • HEISEI YAKUHIN CO., LTD.
  • IZUTSU KURAYA SANSEIDO Inc.
  • IZUTSU PHARMACEUTICAL CO. LTD.
  • Japanese Pharmaceutical Wholesalers Association
  • Jingu Yakuhin Co., Ltd.
  • Johnson & Johnson
  • Katren
  • Kenzmedico Co., Ltd.
  • Kerr Drug
  • KOBASHOU. CO., LTD.
  • KURAYA SANSEIDO Inc
  • Life Medicom Co., Ltd.
  • Lloyds Pharmacy
  • MARUZEN YAKUHIN CO., LTD.
  • McKesson
  • McQueary Brothers of Springfield
  • Medical Specialties Distributors
  • MEDICEO CORPORATION
  • Medicine Shoppe Canada Inc.
  • MEDIE Co., Ltd.
  • MEDIPAL HOLDINGS CORPORATION
  • Mediq Apotheken Nederland B.V.
  • Medtronic
  • Meinan Distribution Center
  • Metro Medical Supply Inc
  • Mitsubishi
  • MM CORPORATION
  • MP AGRO CO., LTD.
  • MVC CO., LTD
  • MWI Veterinary Supply, Inc.
  • Nadro
  • Nakano Yakuhin Co., Ltd.
  • National Health Service (NHS)
  • National Pharmaceutical Pricing Authority (NPPA)
  • Nihon Apoch Co.
  • Novo Nordisk
  • Novodata Zrt.
  • Numark
  • OCP
  • Oncology Therapeutics
  • Oncoprod
  • OptumRx
  • P.J.D. Network
  • PALTAC CORPORATION
  • Paltac Corporation
  • Paltac Corporation
  • PALTAC KS CORPORATION
  • Panpharma
  • Pfercos Co., Ltd.
  • Pfizer
  • PharMEDium
  • Polska Grupa Farmaceutyczna
  • Profarma
  • Prosper
  • Protek
  • PSC Co, Ltd.
  • PSS World Medical Inc.
  • Ratiopharm
  • RDC Kanto5
  • Red Oak Sourcing
  • Red Oak, LLC
  • Rexall Health
  • Rite Aid Corporation
  • Rosta
  • RxCrossroads
  • S. D.Collabo Co.,Ltd.
  • S.D.Logi CO., Ltd.
  • Sakurai Tsusho Corporation
  • Sanacorp
  • Sandoz
  • Sanki Corporation
  • Sanki MediHeart Limited
  • Sanki Wellbe
  • Sanki Wellbe Co., Ltd.
  • Sannova
  • Sanwa Kagaku Kenkyusho Co., Ltd.
  • S-Care Mate Co., Ltd.
  • Sciclone Trade
  • SEIWA SANGYO CO
  • Shanghai Fosun Pharmaceutical
  • Shanghai Pharma Zhenjiang Co., Ltd.
  • Shanghai Pharmaceutical Holdings
  • Shinohara Chemicals
  • Shinsegai Group
  • Shoyaku Co., Ltd.
  • SIA International
  • Sincamesp
  • SINOPHARM
  • S-mile, Inc
  • Sonexus Health
  • SPH Jiangxi Shangrao Pharmaceutical Co., Ltd.
  • SPH Keyuan Xinhai Pharmaceutical Hebei Co., Ltd.
  • SPH Keyuan Xinhai Pharmaceutical Heilongjiang Co., Ltd.
  • SPLine Corporation
  • SUZUKEN
  • Suzuken Co., Ltd.
  • Suzuken Iwate Co., Ltd.
  • Suzuken Medical Instruments Co, Ltd
  • Suzuken Okinawa Yakuhin Co., Ltd.
  • The PHOENIX Group
  • Toho Holdings
  • Tokiwa Yakuhin Co
  • Torfarm
  • Tradex International
  • TS Alfresa Corporation
  • UniChem
  • US Oncology Holdings, Inc.
  • USHIODA KURAYA SANSEIDO Inc.
  • USHIODA SANGOKUDO YAKUHIN CO., LTD.
  • Vaccine Safe Co
  • Vantage Oncology
  • Victoria Merger Sub, Inc.
  • Vitaco Holdings
  • Walgreen
  • Walgreens Boots Alliance
  • World Courier Group Inc.
  • Wyeth Pharmaceuticals
  • YAMAHIRO KURAYA SANSEIDO Inc.
  • Yunnan Pharmaceutical Co., Ltd.
  • Zuellig Pharma
目次
Product Code: PHA0526

The pharma wholesale and distribution market is estimated to grow at a CAGR of 5% in the first half of the forecast period. The market is estimated to reach a revenue of $1,447bn in 2025. In 2018, the branded drugs submarket held 78% of the pharma wholesale and distribution market.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 217-page report you will receive 135 charts - all unavailable elsewhere.

The 217-page report provides clear detailed insight into the pharma wholesale and distribution market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Pharma Wholesale and Distribution Market from 2020-2030

Forecast of the Global Pharma Wholesale and Distribution market by Category:

  • Generic Drugs
  • Branded Drugs
  • Others

This report provides individual revenue forecasts to 2030 for these national markets:

  • US
  • Germany
  • France
  • Italy
  • Spain
  • UK
  • Japan
  • China
  • Brazil
  • India
  • Russia
  • RoW

Each National Market is further segmented into generic drugs, branded drugs and others

Our study discusses the selected leading companies that are the major players in the global pharma and wholesale distribution market:

  • Alfresa Holdings
  • AmerisourceBergen
  • Cardinal Health
  • CR Pharmaceuticals
  • CuraScript SD
  • McKesson
  • Medipal Holdings Corporation
  • Morris and Dickson
  • Mutual Drug Company
  • PHOENIX Group
  • Shanghai Fosun Pharmaceuticals
  • Sinopharm
  • Suzuken
  • Walgreens Boots Alliance

This report provides a SWOT and STEP analysis of the pharma wholesale and distribution market.

Visiongain's study is intended for anyone requiring commercial analyses for the pharma wholesale and distribution market. You find data, trends and predictions.

Buy our report today Pharma Wholesale and Distribution Market Forecasts 2020-2030: Branded Drugs, Generic Drugs, US, China, Japan, Germany, France, Brazil, Italy, Spain, UK, India, Russia, RoW.

Visiongain is a trading partner with the US Federal Government.

Table of Contents

1. Report Overview

  • 1.1 Global Pharma Wholesale and Distribution Industry and Market Overview
  • 1.2 Benefits of This Report
  • 1.3 How This Report Delivers
  • 1.4 Questions Answered by This Analytical Report
  • 1.5 Who is This Report For?
  • 1.6 Methodology
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to Pharma Wholesale and Distribution

  • 2.1 The Role of Pharmaceutical Wholesalers: The Middlemen of the Pharmaceutical Industry
    • 2.1.1 Full-Line Wholesalers (FLWs)
    • 2.1.2 Short-Line Wholesalers (SLWs)
  • 2.2 The Chain of Distribution: Wholesalers vs. Logistic Service Providers
    • 2.2.1 Secondary Wholesalers
    • 2.2.2 Direct-to-Pharmacy (DTP) Distribution is Becoming More Prevalent
    • 2.2.3 Major Wholesalers: Distribution of a Large Number of Products to Generate High Profits
    • 2.2.4 Distribution from Large to Small Wholesalers: A Lengthy Distribution Chain
    • 2.2.5 Pharmacy Benefit Managers
  • 2.3 Generative Revenue and Profit
    • 2.3.1 Forward Buying to Avoid Price Increases
    • 2.3.2 Fee-for-Service: A Clear Pricing Structure
      • 2.3.2.1 Inventory Management Agreements
    • 2.3.3 Discounts: Incentives for Prompt Payment or Bulk Purchases
    • 2.3.4 Reimbursement and Wholesalers
    • 2.3.5 Clawback: The Recovery of Reimbursement Costs by Governments
    • 2.3.6 Parallel Trade: Different Attitudes in Europe and the US

3. The World Pharmaceutical Wholesale and Distribution Market: 2020-2030

  • 3.1 The World Pharmaceutical Wholesale and Distribution Market, Restricted by Government Price Reductions and Generic Substitution
  • 3.2 The Pharmaceutical Wholesale and Distribution Industry: World Market Forecast, 2018-2030
  • 3.3 Branded and Generic Drugs: Revenue vs. Profit, 2018-2030
    • 3.3.1 Branded and Generic Drugs: Revenue Generation, 2017
    • 3.3.2 Branded Drugs: Revenue Forecast, 2018-2030
    • 3.3.3 Generic Drugs: Revenue Forecast, 2018-2030

4. Pharmaceutical Wholesale and Distribution Industry: Leading National Markets, 2020-2030

  • 4.1 The Leading National Markets: the US Dominates in 2018
  • 4.2 The Future of the Leading National Markets: Will the US Continue to Dominate the Market?
  • 4.3 The US Pharma Wholesale and Distribution Market
    • 4.3.1 Specialty Pharmacies Hinders the Growth of Wholesaler's Business
    • 4.3.2 The Budget Control Act and its Effect on the US Wholesale and Distribution Industry
    • 4.3.3 Legislation to Prevent Counterfeit Drugs Can Differ Between States
    • 4.3.4 An Increase in Fee-For-Service Activity
    • 4.3.5 Pharma Wholesale and Distribution Market in the US: Market Forecast, 2018-2030
  • 4.4 The Leading European (EU5) Pharma Wholesale and Distribution Markets
    • 4.4.1 The Difference Between the US and European Markets
    • 4.4.2 State-Funded Healthcare and Reimbursement
    • 4.4.3 EU5: Market Forecast, 2018-2030
    • 4.4.4 Germany: Pharma Wholesale and Distribution Market
      • 4.4.4.1 Healthcare Reform
      • 4.4.4.2 Germany: Reform of AMNOG Pharmaceutical Rebate Law
      • 4.4.4.3 Germany Pharma Wholesale and Distribution Market Forecast, 2018-2030
    • 4.4.5 France: Pharma Wholesale and Distribution Market
      • 4.4.5.1 France: Social Security Finance Bill 2015
      • 4.4.5.2 France: Pharma Wholesale and Distribution Market Forecast, 2018-2030
    • 4.4.6 Italy: Pharma Wholesale and Distribution Market
      • 4.4.6.1 Italy: Pharma Wholesale and Distribution Market Forecast, 2018-2030
    • 4.4.7 Spain: Pharma Wholesale and Distribution Market
      • 4.4.7.1 Spain: Pharma Wholesale and Distribution Market Forecast, 2018-2030
    • 4.4.8 UK: Pharma Wholesale and Distribution Market
      • 4.4.8.1 Price Cuts in the UK
      • 4.4.8.2 Surge in Price of Generic Drugs
      • 4.4.8.3 UK: Pharma Wholesale and Distribution Market Forecast, 2018-2030
  • 4.5 Japan: Pharma Wholesale and Distribution Market
    • 4.5.1 Drug Pricing and Performing Fees in Japan
    • 4.5.2 Japan: Pharma Wholesale and Distribution Market Forecast, 2018-2030
  • 4.6 China: Pharma Wholesale and Distribution Market
    • 4.6.1 China: Leading Pharma Wholesale and Distribution Companies
    • 4.6.2 China: Pharma Wholesale and Distribution Market Forecast, 2018-2030
  • 4.7 Brazil: Pharma and Wholesale Distribution Market
    • 4.7.1 Drug Price Controls in Brazil
    • 4.7.2 Brazil: Pharma Wholesale and Distribution Market Forecast, 2018-2030
  • 4.8 India: Pharma Wholesale and Distribution Market
    • 4.8.1 India: Pharma Wholesale and Distribution Market Forecast, 2018-2030
  • 4.9 Russia: Pharma Wholesale and Distribution Market, 2016
    • 4.9.1 Drug Pricing Controls in Russia
    • 4.9.2 Market Trends in Russia
    • 4.9.3 Russia: Pharma Wholesale and Distribution Market Forecast, 2018-2030
  • 4.10 Conclusion

5. Leading Pharma Wholesalers and Distributors:

  • 5.1 The Leading Pharma Wholesalers and Distribution Companies, 2018
  • 5.2 Leading Pharma Wholesale and Distribution Companies, Drivers and Restraints
  • 5.3 McKesson Corporation
    • 5.3.1 McKesson: Sales and Recent Performance Analysis, 2019
    • 5.3.2 Future Strategies: Consummate Acquisitions to Complement Existing Business or Expand Businesses
    • 5.3.3 McKesson: Recent Developments, 2016-2019
      • 5.3.3.1 Acquisition of Medical Specialties Distributors
      • 5.3.3.2 Acquisition of GMD Distribution, Inc.
      • 5.3.3.3 Partnership with Walmart
      • 5.3.3.4 Acquisition of UDG's Irish Pharmaceutical Distribution Business
  • 5.4 Cardinal Health
    • 5.4.1 Cardinal Health: Sales and Recent Performance Analysis, 2018
    • 5.4.2 Will CVS Joint Venture and Acquisitions Stimulate Future Growth?
    • 5.4.3 Cardinal Health: Recent Developments, 2016-2019
      • 5.4.3.1 Closing of pharmaceutical packaging center and a distribution warehouse
      • 5.4.3.2 Divestiture of Cardinal Health's China Business
  • 5.5 AmerisourceBergen
    • 5.5.1 AmerisourceBergen: Sales and Recent Performance Analysis, 2018
    • 5.5.2 Will Contracts with Walgreens and Alliance Boots Drive Future Growth?
    • 5.5.3 AmerisourceBergen: Recent Developments, 2016-2019
      • 5.5.3.1 Closing of California Distribution Center
      • 5.5.3.2 Joint Venture with Profarma Distribuidora
      • 5.5.3.3 Acquisition of H.D.Smith
  • 5.6 Walgreens Boots Alliance
    • 5.6.1 Walgreens Boots Alliance, Sales and Recent Performance Analysis, 2018
    • 5.6.2 Walgreen Boots Alliance: Recent Developments, 2016-2019
  • 5.7 Medipal Holdings Corporation
    • 5.7.1 Medipal: Sales and Recent Performance Analysis, 2018
    • 5.7.2 Future Strategies of Medipal Holdings Corporation: Revised Business Portfolio with Diverse Sources of Earnings
    • 5.7.3 Medipal: Recent Developments, 2016-2019
  • 5.8 Phoenix Group
    • 5.8.1 The PHOENIX Group: Sales and Recent Performance Analysis, 2018
    • 5.8.2 Future Strategies of the PHOENIX Group: Selective Acquisition
    • 5.8.3 Phoenix Group: Recent Developments, 2016-2019
      • 5.8.3.1 Acquisition of Farmexim S.A. and the Help Net Farma S.A.
  • 5.9 Sinopharm Group Co. Ltd.
    • 5.9.1 Sinopharm, Sales and Recent Performance Analysis, 2018
    • 5.9.2 Future Strategies of Sinopharm: Provide Comprehensive Services and Wider Business Coverage
    • 5.9.3 Sinopharm: Recent Developments, 2016-2019
  • 5.10 Alfresa Holdings Corporation
    • 5.10.1 Alfresa, Sales and Recent Performance Analysis, 2018
    • 5.10.2 Alfresa: Recent Developments, 2016-2019
  • 5.11 Suzuken Co., Ltd
    • 5.11.1 Suzuken Co. Ltd, Sales and Recent Performance Analysis, 2018
    • 5.11.2 Future Strategies of Suzuken CO., LTD: Five Growth Initiatives and Special Focus on Diabetes Field
    • 5.11.3 Suzuken: Recent Developments, 2016-2019
      • 5.11.3.1 Collaboration with Toho Holdings Co., Ltd.
      • 5.11.3.2 Collaboration with World Courier
      • 5.11.3.3 Agreement with AmerisourceBergen
  • 5.12 Shanghai Fosun Pharmaceuticals Co. Ltd.
    • 5.12.1 Shanghai Fosun Pharmaceuticals, Sales and Recent Performance Analysis, 2018
    • 5.12.2 Future Strategies of Shanghai Fosun Pharma: Expansion of Three Leading Regions in China
    • 5.12.3 Shanghai Fosun Pharmaceuticals: Recent Developments, 2016-2019
      • 5.12.3.1 Acquisition of Cardinal Health's China Business
      • 5.12.3.2 Acquisition of Tridem Pharma
  • 5.13 CR Pharmaceuticals
    • 5.13.1 CR Pharmaceuticals: Sales and Recent Performance Analysis, 2018
    • 5.13.2 CR Pharmaceuticals: Recent Developments
      • 5.13.2.1 Strategic cooperation agreement with Novartis
      • 5.13.2.2 Collaboration with China Merchants Bank and Shenzhen Qianhai WeBank
  • 5.14 Morris and Dickson
    • 5.14.1 Morris and Dickson: Sales and Recent Performance Analysis, 2018
    • 5.14.2 Morris and Dickson: Recent Developments
    • 5.14.3 Smith Drug Company
    • 5.14.4 Smith Drug Company: Sales and Recent Performance Analysis, 2018
    • 5.14.5 Smith Drug Company: Recent Developments
  • 5.15 CuraScript SD
    • 5.15.1 CuraScript SD: Sales and Recent Performance Analysis, 2018
    • 5.15.2 CuraScript SD: Recent Developments
  • 5.16 Mutual Drug Company
    • 5.16.1 Mutual Drug Company: Sales and Recent Performance Analysis, 2018
    • 5.16.2 Mutual Drug Company: Recent Developments

6. Qualitative Analysis of The Pharma Wholesale and Distribution Market

  • 6.1 The Strengths and Weaknesses of the Pharma Wholesale and Distribution Market
    • 6.1.1 The Insatiable Demand for Drugs: A Recession Proof Industry?
    • 6.1.2 Wholesalers Do More than Deliver Drugs
      • 6.1.2.1 Pre-Wholesaling: More Prevalent in Europe
      • 6.1.2.2 Through Pre-Financing, Full-Line Wholesalers Finance the Entire Medicines Market
    • 6.1.3 Large Companies Dominate the Market
    • 6.1.4 Despite High Revenues, Profit Margins Are Low
    • 6.1.5 Government-Induced Drug Price Pressures Restrict Profits
    • 6.1.6 The Problem of Counterfeit Drugs
  • 6.2 The Opportunities and Threats of the Pharma Wholesale and Distribution Market, 2018-2030
    • 6.2.1 The Demand for Pharmaceuticals is Increasing
    • 6.2.2 The Increasing Use of Specialty Drugs Will Drive Growth
    • 6.2.3 The Increasing Use of Generic Drugs Will Limit Revenue but Drive Profit Generation
    • 6.2.4 The Promotion of Drug Therapy in the US
    • 6.2.5 Globalisation: The Major National Markets are Dominated by Few Companies
    • 6.2.6 Increased Adoption of the DTP Distribution Model
      • 6.2.6.1 DTP in Europe: The First Place the Scheme Has Taken Hold
      • 6.2.6.2 DTP in the UK Since 1991
      • 6.2.6.3 DTP in Poland: The Second European Country to Adopt the DTP Model
      • 6.2.6.4 Further Expansion of the DTP Model
    • 6.2.7 The Threat of Healthcare Budget Cuts
      • 6.2.7.1 Healthcare Budget Cuts in Germany
      • 6.2.7.2 Healthcare Budget Cuts in France
      • 6.2.7.3 Healthcare Budget Cuts in Italy
      • 6.2.7.4 Healthcare Budget Cuts in Spain
      • 6.2.7.5 Healthcare Budget Cuts in the UK
    • 6.2.8 Do Large Pharmacy Chains Pose a Threat?
      • 6.2.8.1 Case Study: Walmart and the $4 Prescription Scheme
      • 6.2.8.2 Vertical Integration of Wholesalers: A Response to the Threat of Pharmacy Chains
    • 6.2.9 Does the Diversion and Re-Importation of Medicines Pose a Threat to the Industry?
    • 6.2.10 The Threat of Industry Consolidation
  • 6.3 Social, Technological, Economic and Political Factors Influencing the Market, 2018-2030 (STEP Analysis)
    • 6.3.1 Political Factor: The Impact of Recent Regulatory Changes in the EU
    • 6.3.2 Political Factor: Combating Counterfeit Medicines
      • 6.3.2.1 The US and E-Pedigree: Becoming Law in California
      • 6.3.2.2 Anti-Counterfeiting Strategies in Other Markets: The Chinese Government is Attempting to Address the Challenge
      • 6.3.2.3 Serialisation for Wholesalers: Opportunity or a Challenge?

7. Conclusions

  • 7.1 Specialty Drug Products to Drive Growth in the Pharma Wholesale and Distribution Market
  • 7.2 The Leading National Pharma Wholesale and Distribution Markets
  • 7.3 The Leading Companies in the Pharma Wholesale and Distribution Industry
  • 7.4 Trends in the Pharma Wholesale and Distribution Industry
    • 7.4.1 Generics Will Threaten Revenue Growth
    • 7.4.2 Manufacturers Will Deliver More Drugs Directly
    • 7.4.3 There Will Be Greater Demand for Specialty Medicines
    • 7.4.4 Consolidation Will Drive Growth
    • 7.4.5 Anti-Counterfeiting Demands Will Add to Wholesalers' Costs

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
Back to Top